Thrivent Financial for Lutherans Purchases 132,453 Shares of Pfizer Inc. $PFE

Thrivent Financial for Lutherans lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 21.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 737,689 shares of the biopharmaceutical company’s stock after purchasing an additional 132,453 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Pfizer were worth $18,796,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its holdings in Pfizer by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after buying an additional 10,198,330 shares during the period. Geode Capital Management LLC lifted its stake in shares of Pfizer by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after purchasing an additional 1,820,634 shares during the period. Norges Bank bought a new stake in shares of Pfizer during the 2nd quarter valued at $2,270,157,000. Charles Schwab Investment Management Inc. lifted its position in Pfizer by 2.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after acquiring an additional 1,135,457 shares during the period. Finally, Fisher Asset Management LLC boosted its position in shares of Pfizer by 2.0% in the 2nd quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock worth $1,172,980,000 after purchasing an additional 950,239 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 3.3%

Shares of PFE stock opened at $25.77 on Wednesday. The stock’s fifty day moving average price is $25.54 and its 200 day moving average price is $25.06. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The company has a market cap of $146.53 billion, a price-to-earnings ratio of 14.98 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The firm had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the prior year, the firm earned $0.63 EPS. The firm’s revenue was down 1.2% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio is 100.00%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Scotiabank started coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price on the stock. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. Finally, TD Cowen reissued a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $28.06.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beat on both EPS and revenue — Pfizer reported $0.66 EPS vs. $0.57 expected and revenue of $17.56B vs. ~$16.9B consensus, showing resilient demand for older drugs like Eliquis that helped offset COVID declines. Reuters: Pfizer beats fourth-quarter profit estimates
• Positive Sentiment: Obesity drug shows promise — Phase 2b data for PF’3944 (MET‑097i) showed up to ~12% weight loss with monthly dosing, supporting Pfizer’s strategy to build an obesity franchise and reduce reliance on COVID sales. BusinessWire: Phase 2b obesity trial results
• Neutral Sentiment: Company reaffirmed 2026 guidance — Pfizer reiterated its modest outlook (under $3 EPS) and reiterated strategic shift post‑Covid; that reduces uncertainty about management’s targets but signals limited near‑term upside. BusinessWire: Press release
• Neutral Sentiment: Analyst stance mixed — some firms (e.g., Goldman Sachs) maintain neutral ratings citing margin pressure and patent risks, keeping expectations tempered. InsiderMonkey: Goldman Sachs note
• Negative Sentiment: Profit and revenue headwinds flagged — management flagged an expected profit decline and analysts note a ~$1.5B near‑term hit from patent cliffs and lower COVID product demand, weighing on valuation. Seeking Alpha: revenue decline / patent cliff note
• Negative Sentiment: Safety and differentiation questions around the obesity drug — some coverage raised questions about side effects and whether monthly dosing will compete with established weekly GLP‑1 drugs (e.g., Lilly’s Zepbound), muting investor enthusiasm. MSN: safety questions
• Negative Sentiment: Vaccines and Covid sales continue to drag — ongoing declines in Covid vaccine/antiviral revenue are pressuring top‑line growth despite gains elsewhere. FT: vaccines weigh on sales

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.